Abstract
We initiated a prospective, single-arm, phase II study to explore the efficacy, safety, and feasibility of neoadjuvant toripalimab plus platinum-doublet chemotherapy in treatment-naive patients with potentially resectable non-small cell lung cancer (NSCLC). The preliminary results of the study have been presented in 2021 WCLC poster 15.02. Here we report updated data (ClinicalTrials.gov: NCT04144608).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
